- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01279070
Efficacy of Repyflec Cognitive Remediation Group Training in Schizophrenia
Efficacy of Repyflec Cognitive Remediation Group Training in Cognition, Functional Outcomes and Psychiatric Symptoms of Outpatients With Schizophrenia.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Barcelona
-
Sant Boi de Llobregat, Barcelona, Spain, 08930
- Parc Sanitari Sant Joan de Déu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of schizophrenia or schizoaffective disorder
- More than 2 years illness duration
- Literate
- Mini Mental Status Examination score over 24
- Global Assessment of Functioning scores between 40 and 70
Exclusion Criteria:
- Current acute illness exacerbation
- Mental Retardation
- Neurological disorder which impairs cognition
- Currently participating in social skills training or cognitive remediation
- Change of antipsychotic medication one month before the trial or during the 40 study weeks
- Diagnosis of alcohol or drug dependence within 6 months of trial commencement.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: REPYFLEC cognitive remediation training
REPYFLEC cognitive remediation as a Problem solving and Cognitive flexibility group training.
|
Comparison of 32 Repyflec group sessions among 32 leisure group sessions where we stimulated non-specific cognitive perform.
Other Names:
|
Active Comparator: Leisure group
Leisure group is a stimulating activity focused on socialization through group dynamics, board games, "coffee and talk".
|
Comparison of 32 Repyflec group sessions among 32 leisure group sessions where we stimulated non-specific cognitive perform.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Executive Function
Time Frame: Change from baseline in executive function at 16 weeks (post-treatment)
|
Behavioral Assessment of the Dysexecutive Syndrome (BADS). This scale evaluates cognitive flexibility, inhibition of impulsive responses, planning and organization, working memory and time-estimation capacity. All subscales (Rule shift cards, Action Program, Key search, Temporal judgment, Zoo map and Six elements) were administered. We used subscales raw scores which run from 0 to 4. The subscales' raw score is summarized and converted to standardized total score which run (min. 12-max. 129). A higher score indicates better performance. |
Change from baseline in executive function at 16 weeks (post-treatment)
|
Executive Function
Time Frame: Change from baseline in executive functioning at 40 weeks
|
Behavioral Assessment of the Dysexecutive Syndrome (BADS) (Wilson et al., 1996). This scale evaluates cognitive flexibility, inhibition of impulsive responses, planning and organization, working memory and time-estimation capacity. All subscales (Rule shift cards, Action Program, Key search, Temporal judgement, Zoo map and Six elements) were administered. We used subscales raw scores which run from 0 to 4. The subscales' raw score is summarized and converted to standardized total score which run (min. 12-max. 129). A higher score indicates better performance. |
Change from baseline in executive functioning at 40 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Psychosocial Functioning
Time Frame: Change from baseline in social functioning scales at 16 weeks
|
The Spanish validation of the Life Skills Profile (LSP)was used. This scale measures functionality in daily life activities such as self-care, social behavior and autonomy. Raw scoring was used for the various subscales which are summarized for the total (min. 39-max. 156) with a higher score indicating a better result. The 5 subscales are: Self-care, Non-turbulence, Social contact, Communication and Responsibility. We used the Spanish validation of the Social Functioning Scale (SFS)for measuring social behavior and relationships, autonomy, employment-occupation and leisure. Raw scoring was used for each subscale and for total score (min. 0-max. 223) with a higher score indicating a better result. All 7 subscales were administered: social engagement/ withdrawal, interpersonal behavior, independence-competence, independence-performance, pro-social activities, recreation and employment/ occupation. |
Change from baseline in social functioning scales at 16 weeks
|
Psychosocial Functioning
Time Frame: Change from baseline in social functioning scales at 40 weeks
|
The Spanish validation of the Life Skills Profile (LSP)was used. This scale measures functionality in daily life activities such as self-care, social behavior and autonomy. Raw scoring was used for the various subscales which are summarized for the total (min. 39-max. 156) with a higher score indicating a better result. The 5 subscales are: Self-care, Non-turbulence, Social contact, Communication and Responsibility. We used the Spanish validation of the Social Functioning Scale (SFS)for measuring social behavior and relationships, autonomy, employment-occupation and leisure. Raw scoring was used for each subscale and for total score (min. 0-max. 223) with a higher score indicating a better result. All 7 subscales were administered: social engagement/ withdrawal, interpersonal behavior, independence-competence, independence-performance, pro-social activities, recreation and employment/ occupation. |
Change from baseline in social functioning scales at 40 weeks
|
Psychiatric Symptoms
Time Frame: Change from baseline in psychiatric symptoms scales at 16 weeks
|
The Spanish validation of the Positive and Negative Syndrome Scale (PANSS) was used for measuring positive, negative and general symptomatology.
Total raw scoring obtained through the sum of the raw scores for each subscale was considered (min.
30-max.
210) with a score of 30 representing an absence of psychiatric symptoms.
|
Change from baseline in psychiatric symptoms scales at 16 weeks
|
Psychiatric Symptoms
Time Frame: Change from baseline in psychiatric symptoms scales at 40 weeks
|
The Spanish validation of the Positive and Negative Syndrome Scale (PANSS) was used for measuring positive, negative and general symptomatology.
Total raw scoring obtained through the sum of the raw scores for each subscale was considered (min.
30-max.
210) with a score of 30 representing an absence of psychiatric symptoms.
|
Change from baseline in psychiatric symptoms scales at 40 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Aida Farreny, PhD Psycho., Fundació Sant Joan de Deu
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REPYFLEC Clinical Trial
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Indication for Modification of Patient Cognitive Status
-
Universidad de BurgosCompletedIndication for Modification of Patient Cognitive StatusSpain
-
Talebian, Alireza, M.D.CompletedIndication for Modification of Patient Psychological Status
-
Boston Scientific CorporationTerminatedIndication for Modification of Patient Physical StatusChina
-
Rajavithi HospitalCompletedIndication for Modification of Patient Status (Diagnosis)Thailand
-
Holux Technology, Inc.Shin Kong Wu Ho-Su Memorial HospitalUnknownIndication for Modification of Patient's Cardiopulmonary StatusTaiwan
-
Wissenschaftliches Institut Bethanien e.VCompletedIndication for Invasive Out-of-hospital VentilationGermany
-
Centre Hospitalier Universitaire DijonCompletedIndication for Surgery of the Posterior Segment Under Locoregional AnaesthesiaFrance
-
Centre Hospitalier Universitaire de BesanconCompletedPatient With an Indication of Colonoscopy for Inflammatory Bowel DiseaseFrance
-
Ajou University School of MedicineCompletedDietary Modification | Alteration of Cognitive Function
-
Chinese PLA General HospitalActive, not recruitingMRI | Neuroplasticity | Microgravity | Repeatable Battery for the Assessment of Neuropsychological StatusChina
Clinical Trials on Repyflec cognitive remediation training
-
Queen's UniversityCompleted
-
Yale UniversityCompletedCancer | Cancer of the ProstateUnited States
-
Science and Research Centre KoperAlbert Einstein College of Medicine; University of Primorska; Vrije Universiteit...CompletedEffects of Cognitive Intervention on Cognition, Mobility and Brain Electrocortical Activity (GIBKOP)Cognitive Impairment | Aging | Cognitive Decline | Motor Coordination or FunctionSlovenia
-
Douglas Mental Health University InstituteMcGill University; Canadian Institutes of Health Research (CIHR)Recruiting
-
Hospital Clinic of BarcelonaInstituto de Salud Carlos III; Centro de Investigación Biomédica en Red de...Completed
-
Universitätsklinikum Hamburg-EppendorfCompleted
-
Centre for Addiction and Mental HealthCompleted
-
Queens College, The City University of New YorkUnknown
-
Hospital Clinic of BarcelonaUniversity of BarcelonaCompleted
-
Hartford HospitalNational Institute of Mental Health (NIMH)Completed